An innovative approach to meeting patient needs
Teva has a world-leading position in innovative treatments for disorders of the central nervous system (CNS), including neurological and neurodegenerative diseases, pain, and movement disorders, as well as a strong portfolio of products to address respiratory disease, including asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD).
Across its specialty medicines portfolio, Teva focuses on developing, personalizing and improving treatment of disorders for patients in CNS, respiratory, oncology, and select local/regional therapeutic areas. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
Our Specialty medicines:
Treatment of chronic lymphocytic leukemia (CLL) & indolent B-cell non-hodgkin's lymphoma (NHL) that has progressed during or w/in 6 mth of treatment w/ rituximab or rituximab containing regimen
Breakthrough pain in adult w/cancer who is already receiving maintenance opioid therapy for chronic cancer pain
Treatment of premenstrual syndrome, including PMT & depression. Treament of puerperal depression. Luteal phase support as part of an Assisted Reproductive Technology (ART) treatment for women
Actonel Once-A-Wk 35mg Treatment of postmenopausal osteoporosis. Prevention of osteoporosis in postmenopausal women w/ increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fractures
Actonel Once-A-Mth 150mg Treatment of postmenopausal osteoporosis
If you have any questions, please consult with your healthcare professionals